December 4, 2020

The Niche

Knoepfler lab stem cell blog

Kapil Bharti

3 min read

The NIH announced the launch of the 1st autologous induced pluripotent stem (IPS) cell trial for vision loss in the U.S., focused on macular degeneration. The protocol is based on a solid foundation of pre-clinical animal studies: “Researchers at the National Eye Institute (NEI) are launching a clinical trial to test the safety of a novel patient-specific stem cell-based therapy to treat geographic atrophy, the advanced “dry” form of age-related macular degeneration (AMD), a leading cause of vision loss among people age 65 and …Read More

3 min read

By Jeanne Loring What can you do with cells that live forever and can make every cell type in the body?  The answer is: remarkable things, as new reports of clinical trials using cell types derived from pluripotent stem cells indicate. Pluripotent stem cells are either derived from embryos donated from IVF procedures (human embryonic stem cells- hESCs) or from cells provided by a person, usually blood or skin (induced pluripotent stem cells- iPSCs).  The stem cells are never used for transplantation; instead, they …Read More